10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx), will deploy its Xenium platform in a 24-month study. The project seeks to identify biomarkers that may predict how patients with breast cancer respond to neoadjuvant therapy, or treatment administered before surgery to shrink tumors. FUSCC and SPDx intend to use the findings from the study to inform their development of potential future diagnostic approaches.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.